Tuesday - July 15, 2025
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
May 22, 2025
LONDON, England, May 22 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

* Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterised by blood eosinophil count (BEC) starting at 150 cells/mL

* . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products